Who
Lauren Riker
Senior Vice President, Finance
Company insider
Files Form 4 as: Senior Vice President, Finance, Pacira BioSciences.
In numbers
- Trades disclosed
- 142
- Buys
- 0
- Sells
- 46
- Bought
- $0
- Sold
- $6.0M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 5 Jun 2012
- Last trade
- 8 Oct 2026
- Last filed
- 9 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Oct 2026filed 9 Oct 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code M | $194K6,000 at $32.35 | filing |
| 8 Oct 2026filed 9 Oct 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $218K6,000 at $36.32 | filing |
| 8 Oct 2026filed 9 Oct 2026 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $144K6,115 at $23.50 | filing |
| 11 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $144K6,115 at $23.50 | filing |
| 3 Jun 2026filed 5 Jun 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $71K3,187 at $22.32 | filing |
| 3 Jun 2026filed 5 Jun 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $71K3,187 at $22.32 | filing |
| 11 Feb 2026filed 13 Feb 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —19,273 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —19,273 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $83K4,000 at $20.81 | filing |
| 2 Feb 2026filed 3 Feb 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $83K4,000 at $20.81 | filing |
| 30 Jan 2026filed 3 Feb 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $57K2,751 at $20.54 | filing |
| 30 Jan 2026filed 3 Feb 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $57K2,751 at $20.54 | filing |
| 5 Jan 2026filed 6 Jan 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $34K1,416 at $24.24 | filing |
| 5 Jan 2026filed 6 Jan 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $34K1,416 at $24.24 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $3,889159 at $24.46 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $3,889159 at $24.46 | filing |
| 4 Jun 2025filed 5 Jun 2025 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $146K5,578.34 at $26.21 | filing |
| 3 Jun 2025filed 5 Jun 2025 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code F | $89K3,374 at $26.40 | filing |
| 1 Feb 2025filed 4 Feb 2025 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —30,600 at $0.00 | filing |
News
Pacira BioSciences (NASDAQ:PCRX) Upgraded at JPMorgan Chase & Co.PCRX · themarketsdaily.com · 11 Oct 2026Insider Selling: Pacira BioSciences (NASDAQ:PCRX) SVP Sells $217,920.00 in StockPCRX · themarketsdaily.com · 10 Oct 2026Pacira BioSciences jumps 44% on Viatris acquisition deal (PCRX:NASDAQ)PCRX · seekingalpha.com · 8 Oct 2026
0 headlines in the last 90 days name Lauren Riker; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.